H.t.C. has received consultancy fees from Aleveron, AstraZeneca, Galapagos and Novostia and research funding from Bayer; all revenues are deposited at the CARIM Institute and labelled for research. H.t.C. is stockholder of Coagulation Profile, a spinoff diagnostic company of Maastricht University. B.G. declares no competing interests.